| Record Information |
|---|
| Version | 5.0 |
|---|
| Status | Expected but not Quantified |
|---|
| Creation Date | 2012-09-06 15:16:49 UTC |
|---|
| Update Date | 2022-03-07 02:51:38 UTC |
|---|
| HMDB ID | HMDB0014465 |
|---|
| Secondary Accession Numbers | |
|---|
| Metabolite Identification |
|---|
| Common Name | Dihydroergotamine |
|---|
| Description | Dihydroergotamine is only found in individuals that have used or taken this drug. It is a 9,10alpha-dihydro derivative of ergotamine. It is used as a vasoconstrictor, specifically for the therapy of migraine disorders. [PubChem]Two theories have been proposed to explain the efficacy of 5-HT1D receptor agonists in migraine: 1) activation of 5-HT1D receptors located on intracranial blood vessels, including those on arterio-venous anastomoses, leads to vasoconstriction, which correlates with the relief of migraine headache and 2) activation of 5-HT1D receptors on sensory nerve endings of the trigeminal system results in the inhibition of pro-inflammatory neuropeptide release. |
|---|
| Structure | [H][C@@]12CCCN1C(=O)[C@H](CC1=CC=CC=C1)N1C(=O)[C@](C)(NC(=O)[C@H]3CN(C)[C@]4([H])CC5=CNC6=CC=CC(=C56)[C@@]4([H])C3)O[C@@]21O InChI=1S/C33H37N5O5/c1-32(35-29(39)21-15-23-22-10-6-11-24-28(22)20(17-34-24)16-25(23)36(2)18-21)31(41)38-26(14-19-8-4-3-5-9-19)30(40)37-13-7-12-27(37)33(38,42)43-32/h3-6,8-11,17,21,23,25-27,34,42H,7,12-16,18H2,1-2H3,(H,35,39)/t21-,23-,25-,26+,27+,32-,33+/m1/s1 |
|---|
| Synonyms | | Value | Source |
|---|
| 5'-Benzyl-12'-hydroxy-2'-methyl-3',6',18-trioxo-9,10-dihydroergotaman | ChEBI | | 9,10-Dihydro-12'-hydroxy-2'-methyl-5'-(phenylmethyl)ergotoman-3',6',18-trione | ChEBI | | 9,10-Dihydroergotamine | ChEBI | | Dihidroergotamina | ChEBI | | Dihydroergotaminum | ChEBI | | Neomigran | Kegg | | 9,10-Dihydro-ergotamine | HMDB | | Dihydroergotamine mesylate | HMDB | | Dihydroergotamine methanesulfonate | HMDB | | Dihydroergotamine monomethanesulfonate | HMDB | | Clavigrenin | HMDB | | D Tamin retard l.u.t. | HMDB | | D.H.E. 45 | HMDB | | DHE 45 | HMDB | | DHE ratiopharm | HMDB | | Desitin brand OF dihydroergotamine mesylate | HMDB | | Methanesulfonate, dihydroergotamine | HMDB | | Orstanorm | HMDB | | Shire brand OF dihydroergotamine mesylate | HMDB | | Wernigeroide brand OF dihydroergotamine mesylate | HMDB | | Alpharma brand OF dihydroergotamine mesylate | HMDB | | Angionorm | HMDB | | Anto brand OF dihydroergotamine mesylate | HMDB | | DHE-puren | HMDB | | Dihydroergotamine-sandoz | HMDB | | Ergomimet | HMDB | | IPRAD brand OF dihydroergotamine mesylate | HMDB | | Ikaran | HMDB | | Migranal | HMDB | | Pierre fabre brand OF dihydroergotamine mesylate | HMDB | | Seglor | HMDB | | Xcel brand 2 OF dihydroergotamine mesylate | HMDB | | CT Arzneimittel brand OF dihydroergotamine mesylate | HMDB | | CT-Arzneimittel brand OF dihydroergotamine mesylate | HMDB | | Agit | HMDB | | DET MS | HMDB | | DHE puren | HMDB | | DHE-ratiopharm | HMDB | | DHE45 | HMDB | | Dihydroergotamin al | HMDB | | Dihytamin | HMDB | | Erganton | HMDB | | Farmasan brand OF dihydroergotamine mesylate | HMDB | | Q-Pharm brand OF dihydroergotamine mesylate | HMDB | | Tamik | HMDB | | Verla brand OF dihydroergotamine mesylate | HMDB | | Xcel brand 1 OF dihydroergotamine mesylate | HMDB | | Ergotam von CT | HMDB | | Aliud brand OF dihydroergotamine mesylate | HMDB | | D-Tamin retard l.u.t. | HMDB | | DHE-45 | HMDB | | Dihydergot | HMDB | | Dihydroergotamine sandoz | HMDB | | Ergont | HMDB | | Fujisawa brand OF dihydroergotamine mesylate | HMDB | | Hormosan brand OF dihydroergotamine mesylate | HMDB | | Mesylate, dihydroergotamine | HMDB | | Novartis brand OF dihydroergotamine mesylate | HMDB | | Pharmafrid brand OF dihydroergotamine mesylate | HMDB | | Q Pharm brand OF dihydroergotamine mesylate | HMDB | | Sanol brand OF dihydroergotamine mesylate | HMDB | | Schwarz brand OF dihydroergotamine mesylate | HMDB | | Verladyn | HMDB | | Ratiopharm brand OF dihydroergotamine mesylate | HMDB | | Von CT, ergotam | HMDB |
|
|---|
| Chemical Formula | C33H37N5O5 |
|---|
| Average Molecular Weight | 583.6774 |
|---|
| Monoisotopic Molecular Weight | 583.279469319 |
|---|
| IUPAC Name | (2R,4R,7R)-N-[(1S,2S,4R,7S)-7-benzyl-2-hydroxy-4-methyl-5,8-dioxo-3-oxa-6,9-diazatricyclo[7.3.0.0²,⁶]dodecan-4-yl]-6-methyl-6,11-diazatetracyclo[7.6.1.0²,⁷.0¹²,¹⁶]hexadeca-1(16),9,12,14-tetraene-4-carboxamide |
|---|
| Traditional Name | dihydroergotamine |
|---|
| CAS Registry Number | 6190-39-2 |
|---|
| SMILES | [H][C@@]12CCCN1C(=O)[C@H](CC1=CC=CC=C1)N1C(=O)[C@](C)(NC(=O)[C@H]3CN(C)[C@]4([H])CC5=CNC6=CC=CC(=C56)[C@@]4([H])C3)O[C@@]21O |
|---|
| InChI Identifier | InChI=1S/C33H37N5O5/c1-32(35-29(39)21-15-23-22-10-6-11-24-28(22)20(17-34-24)16-25(23)36(2)18-21)31(41)38-26(14-19-8-4-3-5-9-19)30(40)37-13-7-12-27(37)33(38,42)43-32/h3-6,8-11,17,21,23,25-27,34,42H,7,12-16,18H2,1-2H3,(H,35,39)/t21-,23-,25-,26+,27+,32-,33+/m1/s1 |
|---|
| InChI Key | LUZRJRNZXALNLM-JGRZULCMSA-N |
|---|
| Chemical Taxonomy |
|---|
| Description | Belongs to the class of organic compounds known as ergotamines, dihydroergotamines, and derivatives. These are organic compounds containing an ergotamine moiety, which is structurally characterized by a benzyl substituent attached to the piperazine ring of the ergopeptine backbone. |
|---|
| Kingdom | Organic compounds |
|---|
| Super Class | Alkaloids and derivatives |
|---|
| Class | Ergoline and derivatives |
|---|
| Sub Class | Lysergic acids and derivatives |
|---|
| Direct Parent | Ergotamines, dihydroergotamines, and derivatives |
|---|
| Alternative Parents | |
|---|
| Substituents | - Dihydroergotamine
- Ergotamine
- Hybrid peptide
- Alpha-dipeptide
- Lysergic acid amide
- Indoloquinoline
- Benzoquinoline
- Quinoline-3-carboxamide
- N-acyl-alpha amino acid or derivatives
- Pyrroloquinoline
- Alpha-amino acid or derivatives
- Quinoline
- 3-alkylindole
- Indole
- Indole or derivatives
- Isoindole or derivatives
- Piperidinecarboxamide
- 3-piperidinecarboxamide
- Aralkylamine
- N-alkylpiperazine
- Benzenoid
- Monocyclic benzene moiety
- 1,4-diazinane
- Oxazolidinone
- Piperazine
- Piperidine
- Tertiary carboxylic acid amide
- Heteroaromatic compound
- Oxazolidine
- Pyrrolidine
- Pyrrole
- Amino acid or derivatives
- Lactam
- Tertiary aliphatic amine
- Secondary carboxylic acid amide
- Orthocarboxylic acid derivative
- Carboxamide group
- Tertiary amine
- Oxacycle
- Organoheterocyclic compound
- Azacycle
- Alkanolamine
- Carboxylic acid derivative
- Organonitrogen compound
- Organic oxygen compound
- Organopnictogen compound
- Carbonyl group
- Organic nitrogen compound
- Amine
- Organooxygen compound
- Organic oxide
- Hydrocarbon derivative
- Aromatic heteropolycyclic compound
|
|---|
| Molecular Framework | Aromatic heteropolycyclic compounds |
|---|
| External Descriptors | |
|---|
| Ontology |
|---|
| Physiological effect | Not Available |
|---|
| Disposition | |
|---|
| Process | Not Available |
|---|
| Role | |
|---|
| Physical Properties |
|---|
| State | Solid |
|---|
| Experimental Molecular Properties | | Property | Value | Reference |
|---|
| Melting Point | Not Available | Not Available | | Boiling Point | Not Available | Not Available | | Water Solubility | 0.23 g/L | Not Available | | LogP | 2 | Not Available |
|
|---|
| Experimental Chromatographic Properties | Not Available |
|---|
| Predicted Molecular Properties | |
|---|
| Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Retention Times Underivatized| Chromatographic Method | Retention Time | Reference |
|---|
| Measured using a Waters Acquity ultraperformance liquid chromatography (UPLC) ethylene-bridged hybrid (BEH) C18 column (100 mm × 2.1 mm; 1.7 μmparticle diameter). Predicted by Afia on May 17, 2022. Predicted by Afia on May 17, 2022. | 5.05 minutes | 32390414 | | Predicted by Siyang on May 30, 2022 | 12.021 minutes | 33406817 | | Predicted by Siyang using ReTip algorithm on June 8, 2022 | 4.24 minutes | 32390414 | | AjsUoB = Accucore 150 Amide HILIC with 10mM Ammonium Formate, 0.1% Formic Acid | 101.9 seconds | 40023050 | | Fem_Long = Waters ACQUITY UPLC HSS T3 C18 with Water:MeOH and 0.1% Formic Acid | 2072.9 seconds | 40023050 | | Fem_Lipids = Ascentis Express C18 with (60:40 water:ACN):(90:10 IPA:ACN) and 10mM NH4COOH + 0.1% Formic Acid | 168.5 seconds | 40023050 | | Life_Old = Waters ACQUITY UPLC BEH C18 with Water:(20:80 acetone:ACN) and 0.1% Formic Acid | 202.6 seconds | 40023050 | | Life_New = RP Waters ACQUITY UPLC HSS T3 C18 with Water:(30:70 MeOH:ACN) and 0.1% Formic Acid | 176.6 seconds | 40023050 | | RIKEN = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 178.2 seconds | 40023050 | | Eawag_XBridgeC18 = XBridge C18 3.5u 2.1x50 mm with Water:MeOH and 0.1% Formic Acid | 359.5 seconds | 40023050 | | BfG_NTS_RP1 =Agilent Zorbax Eclipse Plus C18 (2.1 mm x 150 mm, 3.5 um) with Water:ACN and 0.1% Formic Acid | 404.3 seconds | 40023050 | | HILIC_BDD_2 = Merck SeQuant ZIC-HILIC with ACN(0.1% formic acid):water(16 mM ammonium formate) | 663.0 seconds | 40023050 | | UniToyama_Atlantis = RP Waters Atlantis T3 (2.1 x 150 mm, 5 um) with ACN:Water and 0.1% Formic Acid | 1035.9 seconds | 40023050 | | BDD_C18 = Hypersil Gold 1.9µm C18 with Water:ACN and 0.1% Formic Acid | 485.9 seconds | 40023050 | | UFZ_Phenomenex = Kinetex Core-Shell C18 2.6 um, 3.0 x 100 mm, Phenomenex with Water:MeOH and 0.1% Formic Acid | 1561.0 seconds | 40023050 | | SNU_RIKEN_POS = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 328.8 seconds | 40023050 | | RPMMFDA = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 332.7 seconds | 40023050 | | MTBLS87 = Merck SeQuant ZIC-pHILIC column with ACN:Water and :ammonium carbonate | 303.5 seconds | 40023050 | | KI_GIAR_zic_HILIC_pH2_7 = Merck SeQuant ZIC-HILIC with ACN:Water and 0.1% FA | 373.7 seconds | 40023050 | | Meister zic-pHILIC pH9.3 = Merck SeQuant ZIC-pHILIC column with ACN:Water 5mM NH4Ac pH9.3 and 5mM ammonium acetate in water | 26.7 seconds | 40023050 |
Predicted Kovats Retention IndicesUnderivatizedDerivatized| Derivative Name / Structure | SMILES | Kovats RI Value | Column Type | Reference |
|---|
| Dihydroergotamine,1TMS,isomer #1 | CN1C[C@H](C(=O)N[C@]2(C)O[C@@]3(O[Si](C)(C)C)[C@@H]4CCCN4C(=O)[C@H](CC4=CC=CC=C4)N3C2=O)C[C@@H]2C3=CC=CC4=C3C(=C[NH]4)C[C@H]21 | 4713.4 | Semi standard non polar | 33892256 | | Dihydroergotamine,1TMS,isomer #2 | CN1C[C@H](C(=O)N([C@]2(C)O[C@@]3(O)[C@@H]4CCCN4C(=O)[C@H](CC4=CC=CC=C4)N3C2=O)[Si](C)(C)C)C[C@@H]2C3=CC=CC4=C3C(=C[NH]4)C[C@H]21 | 4614.2 | Semi standard non polar | 33892256 | | Dihydroergotamine,1TMS,isomer #3 | CN1C[C@H](C(=O)N[C@]2(C)O[C@@]3(O)[C@@H]4CCCN4C(=O)[C@H](CC4=CC=CC=C4)N3C2=O)C[C@@H]2C3=CC=CC4=C3C(=CN4[Si](C)(C)C)C[C@H]21 | 4701.2 | Semi standard non polar | 33892256 | | Dihydroergotamine,2TMS,isomer #1 | CN1C[C@H](C(=O)N([C@]2(C)O[C@@]3(O[Si](C)(C)C)[C@@H]4CCCN4C(=O)[C@H](CC4=CC=CC=C4)N3C2=O)[Si](C)(C)C)C[C@@H]2C3=CC=CC4=C3C(=C[NH]4)C[C@H]21 | 4624.3 | Semi standard non polar | 33892256 | | Dihydroergotamine,2TMS,isomer #1 | CN1C[C@H](C(=O)N([C@]2(C)O[C@@]3(O[Si](C)(C)C)[C@@H]4CCCN4C(=O)[C@H](CC4=CC=CC=C4)N3C2=O)[Si](C)(C)C)C[C@@H]2C3=CC=CC4=C3C(=C[NH]4)C[C@H]21 | 4804.3 | Standard non polar | 33892256 | | Dihydroergotamine,2TMS,isomer #1 | CN1C[C@H](C(=O)N([C@]2(C)O[C@@]3(O[Si](C)(C)C)[C@@H]4CCCN4C(=O)[C@H](CC4=CC=CC=C4)N3C2=O)[Si](C)(C)C)C[C@@H]2C3=CC=CC4=C3C(=C[NH]4)C[C@H]21 | 6065.9 | Standard polar | 33892256 | | Dihydroergotamine,2TMS,isomer #2 | CN1C[C@H](C(=O)N[C@]2(C)O[C@@]3(O[Si](C)(C)C)[C@@H]4CCCN4C(=O)[C@H](CC4=CC=CC=C4)N3C2=O)C[C@@H]2C3=CC=CC4=C3C(=CN4[Si](C)(C)C)C[C@H]21 | 4666.8 | Semi standard non polar | 33892256 | | Dihydroergotamine,2TMS,isomer #2 | CN1C[C@H](C(=O)N[C@]2(C)O[C@@]3(O[Si](C)(C)C)[C@@H]4CCCN4C(=O)[C@H](CC4=CC=CC=C4)N3C2=O)C[C@@H]2C3=CC=CC4=C3C(=CN4[Si](C)(C)C)C[C@H]21 | 4728.0 | Standard non polar | 33892256 | | Dihydroergotamine,2TMS,isomer #2 | CN1C[C@H](C(=O)N[C@]2(C)O[C@@]3(O[Si](C)(C)C)[C@@H]4CCCN4C(=O)[C@H](CC4=CC=CC=C4)N3C2=O)C[C@@H]2C3=CC=CC4=C3C(=CN4[Si](C)(C)C)C[C@H]21 | 6064.5 | Standard polar | 33892256 | | Dihydroergotamine,2TMS,isomer #3 | CN1C[C@H](C(=O)N([C@]2(C)O[C@@]3(O)[C@@H]4CCCN4C(=O)[C@H](CC4=CC=CC=C4)N3C2=O)[Si](C)(C)C)C[C@@H]2C3=CC=CC4=C3C(=CN4[Si](C)(C)C)C[C@H]21 | 4589.6 | Semi standard non polar | 33892256 | | Dihydroergotamine,2TMS,isomer #3 | CN1C[C@H](C(=O)N([C@]2(C)O[C@@]3(O)[C@@H]4CCCN4C(=O)[C@H](CC4=CC=CC=C4)N3C2=O)[Si](C)(C)C)C[C@@H]2C3=CC=CC4=C3C(=CN4[Si](C)(C)C)C[C@H]21 | 4721.6 | Standard non polar | 33892256 | | Dihydroergotamine,2TMS,isomer #3 | CN1C[C@H](C(=O)N([C@]2(C)O[C@@]3(O)[C@@H]4CCCN4C(=O)[C@H](CC4=CC=CC=C4)N3C2=O)[Si](C)(C)C)C[C@@H]2C3=CC=CC4=C3C(=CN4[Si](C)(C)C)C[C@H]21 | 6078.6 | Standard polar | 33892256 | | Dihydroergotamine,3TMS,isomer #1 | CN1C[C@H](C(=O)N([C@]2(C)O[C@@]3(O[Si](C)(C)C)[C@@H]4CCCN4C(=O)[C@H](CC4=CC=CC=C4)N3C2=O)[Si](C)(C)C)C[C@@H]2C3=CC=CC4=C3C(=CN4[Si](C)(C)C)C[C@H]21 | 4611.1 | Semi standard non polar | 33892256 | | Dihydroergotamine,3TMS,isomer #1 | CN1C[C@H](C(=O)N([C@]2(C)O[C@@]3(O[Si](C)(C)C)[C@@H]4CCCN4C(=O)[C@H](CC4=CC=CC=C4)N3C2=O)[Si](C)(C)C)C[C@@H]2C3=CC=CC4=C3C(=CN4[Si](C)(C)C)C[C@H]21 | 4729.3 | Standard non polar | 33892256 | | Dihydroergotamine,3TMS,isomer #1 | CN1C[C@H](C(=O)N([C@]2(C)O[C@@]3(O[Si](C)(C)C)[C@@H]4CCCN4C(=O)[C@H](CC4=CC=CC=C4)N3C2=O)[Si](C)(C)C)C[C@@H]2C3=CC=CC4=C3C(=CN4[Si](C)(C)C)C[C@H]21 | 5821.5 | Standard polar | 33892256 | | Dihydroergotamine,1TBDMS,isomer #1 | CN1C[C@H](C(=O)N[C@]2(C)O[C@@]3(O[Si](C)(C)C(C)(C)C)[C@@H]4CCCN4C(=O)[C@H](CC4=CC=CC=C4)N3C2=O)C[C@@H]2C3=CC=CC4=C3C(=C[NH]4)C[C@H]21 | 4908.4 | Semi standard non polar | 33892256 | | Dihydroergotamine,1TBDMS,isomer #2 | CN1C[C@H](C(=O)N([C@]2(C)O[C@@]3(O)[C@@H]4CCCN4C(=O)[C@H](CC4=CC=CC=C4)N3C2=O)[Si](C)(C)C(C)(C)C)C[C@@H]2C3=CC=CC4=C3C(=C[NH]4)C[C@H]21 | 4815.5 | Semi standard non polar | 33892256 | | Dihydroergotamine,1TBDMS,isomer #3 | CN1C[C@H](C(=O)N[C@]2(C)O[C@@]3(O)[C@@H]4CCCN4C(=O)[C@H](CC4=CC=CC=C4)N3C2=O)C[C@@H]2C3=CC=CC4=C3C(=CN4[Si](C)(C)C(C)(C)C)C[C@H]21 | 4880.9 | Semi standard non polar | 33892256 | | Dihydroergotamine,2TBDMS,isomer #1 | CN1C[C@H](C(=O)N([C@]2(C)O[C@@]3(O[Si](C)(C)C(C)(C)C)[C@@H]4CCCN4C(=O)[C@H](CC4=CC=CC=C4)N3C2=O)[Si](C)(C)C(C)(C)C)C[C@@H]2C3=CC=CC4=C3C(=C[NH]4)C[C@H]21 | 4990.7 | Semi standard non polar | 33892256 | | Dihydroergotamine,2TBDMS,isomer #1 | CN1C[C@H](C(=O)N([C@]2(C)O[C@@]3(O[Si](C)(C)C(C)(C)C)[C@@H]4CCCN4C(=O)[C@H](CC4=CC=CC=C4)N3C2=O)[Si](C)(C)C(C)(C)C)C[C@@H]2C3=CC=CC4=C3C(=C[NH]4)C[C@H]21 | 5241.0 | Standard non polar | 33892256 | | Dihydroergotamine,2TBDMS,isomer #1 | CN1C[C@H](C(=O)N([C@]2(C)O[C@@]3(O[Si](C)(C)C(C)(C)C)[C@@H]4CCCN4C(=O)[C@H](CC4=CC=CC=C4)N3C2=O)[Si](C)(C)C(C)(C)C)C[C@@H]2C3=CC=CC4=C3C(=C[NH]4)C[C@H]21 | 6092.5 | Standard polar | 33892256 | | Dihydroergotamine,2TBDMS,isomer #2 | CN1C[C@H](C(=O)N[C@]2(C)O[C@@]3(O[Si](C)(C)C(C)(C)C)[C@@H]4CCCN4C(=O)[C@H](CC4=CC=CC=C4)N3C2=O)C[C@@H]2C3=CC=CC4=C3C(=CN4[Si](C)(C)C(C)(C)C)C[C@H]21 | 5034.9 | Semi standard non polar | 33892256 | | Dihydroergotamine,2TBDMS,isomer #2 | CN1C[C@H](C(=O)N[C@]2(C)O[C@@]3(O[Si](C)(C)C(C)(C)C)[C@@H]4CCCN4C(=O)[C@H](CC4=CC=CC=C4)N3C2=O)C[C@@H]2C3=CC=CC4=C3C(=CN4[Si](C)(C)C(C)(C)C)C[C@H]21 | 5143.9 | Standard non polar | 33892256 | | Dihydroergotamine,2TBDMS,isomer #2 | CN1C[C@H](C(=O)N[C@]2(C)O[C@@]3(O[Si](C)(C)C(C)(C)C)[C@@H]4CCCN4C(=O)[C@H](CC4=CC=CC=C4)N3C2=O)C[C@@H]2C3=CC=CC4=C3C(=CN4[Si](C)(C)C(C)(C)C)C[C@H]21 | 6112.5 | Standard polar | 33892256 | | Dihydroergotamine,2TBDMS,isomer #3 | CN1C[C@H](C(=O)N([C@]2(C)O[C@@]3(O)[C@@H]4CCCN4C(=O)[C@H](CC4=CC=CC=C4)N3C2=O)[Si](C)(C)C(C)(C)C)C[C@@H]2C3=CC=CC4=C3C(=CN4[Si](C)(C)C(C)(C)C)C[C@H]21 | 4963.9 | Semi standard non polar | 33892256 | | Dihydroergotamine,2TBDMS,isomer #3 | CN1C[C@H](C(=O)N([C@]2(C)O[C@@]3(O)[C@@H]4CCCN4C(=O)[C@H](CC4=CC=CC=C4)N3C2=O)[Si](C)(C)C(C)(C)C)C[C@@H]2C3=CC=CC4=C3C(=CN4[Si](C)(C)C(C)(C)C)C[C@H]21 | 5120.3 | Standard non polar | 33892256 | | Dihydroergotamine,2TBDMS,isomer #3 | CN1C[C@H](C(=O)N([C@]2(C)O[C@@]3(O)[C@@H]4CCCN4C(=O)[C@H](CC4=CC=CC=C4)N3C2=O)[Si](C)(C)C(C)(C)C)C[C@@H]2C3=CC=CC4=C3C(=CN4[Si](C)(C)C(C)(C)C)C[C@H]21 | 6128.0 | Standard polar | 33892256 |
|
|---|
| GC-MS Spectra| Spectrum Type | Description | Splash Key | Deposition Date | Source | View |
|---|
| Predicted GC-MS | Predicted GC-MS Spectrum - Dihydroergotamine GC-MS (Non-derivatized) - 70eV, Positive | splash10-0fr5-5891210000-f53c38352e2598f9007e | 2017-09-01 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Dihydroergotamine GC-MS (1 TMS) - 70eV, Positive | splash10-0fdn-7491022000-6c73d0337e04ab2f6918 | 2017-10-06 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Dihydroergotamine GC-MS ("Dihydroergotamine,1TMS,#1" TMS) - 70eV, Positive | Not Available | 2021-10-14 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Dihydroergotamine GC-MS (TMS_1_2) - 70eV, Positive | Not Available | 2021-10-15 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Dihydroergotamine GC-MS (TMS_1_3) - 70eV, Positive | Not Available | 2021-10-15 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Dihydroergotamine GC-MS (TBDMS_1_1) - 70eV, Positive | Not Available | 2021-10-15 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Dihydroergotamine GC-MS (TBDMS_1_2) - 70eV, Positive | Not Available | 2021-10-15 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Dihydroergotamine GC-MS (TBDMS_1_3) - 70eV, Positive | Not Available | 2021-10-15 | Wishart Lab | View Spectrum |
MS/MS Spectra| Spectrum Type | Description | Splash Key | Deposition Date | Source | View |
|---|
| Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Dihydroergotamine 10V, Positive-QTOF | splash10-001i-0022090000-bfd200952b03e8b137ff | 2016-08-01 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Dihydroergotamine 20V, Positive-QTOF | splash10-0un9-0091010000-c5661ba02ab58100d046 | 2016-08-01 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Dihydroergotamine 40V, Positive-QTOF | splash10-004i-4590000000-dc4a0cca36e4ae6c18c5 | 2016-08-01 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Dihydroergotamine 10V, Negative-QTOF | splash10-0019-0049160000-4fdc70b6d84db2eb175e | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Dihydroergotamine 20V, Negative-QTOF | splash10-03xr-2196220000-3c3fcf127102792f663c | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Dihydroergotamine 40V, Negative-QTOF | splash10-0g4j-9810000000-88f13186254d2bf07e89 | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Dihydroergotamine 10V, Positive-QTOF | splash10-001i-0000090000-3abf973bfa14967f7f1d | 2021-09-22 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Dihydroergotamine 20V, Positive-QTOF | splash10-001i-0010290000-1037c6e147fa5f93e653 | 2021-09-22 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Dihydroergotamine 40V, Positive-QTOF | splash10-004i-0090010000-f5347f35594f87c4297f | 2021-09-22 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Dihydroergotamine 10V, Negative-QTOF | splash10-001i-0000090000-10b01aae8e192c05edc6 | 2021-09-22 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Dihydroergotamine 20V, Negative-QTOF | splash10-001i-2100390000-475a2b73d09ae5f9c174 | 2021-09-22 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Dihydroergotamine 40V, Negative-QTOF | splash10-0v03-9351430000-9c41d997e0687489c4ee | 2021-09-22 | Wishart Lab | View Spectrum |
|
|---|